1. S695 Risankizumab Induces Early Clinical Remission and Response in Patients With Moderate-To-Severe Crohn's Disease: Results From the Phase 3 ADVANCE and MOTIVATE Studies. (October 2021) Authors: Schreiber, Stefan; Ferrante, Marc; Panaccione, Remo; Colombel, Jean-Frederic; Hisamatsu, Tadakazu; Lim, Allen; Lindsay, James; Rubin, David T.; Sandborn, William; Neimark, Ezequiel; Song, Alexandra; Liao, Xiaomei; Feng, Tian; Berg, Sofie; Wallace, Kori; D'Haens, Geert Journal: American journal of gastroenterology Issue: Volume 116:Supplement(2021)ACG Annual Meeting Abstracts 1 Page Start: S314 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A randomized controlled trial of a multicomponent online stress reduction intervention in inflammatory bowel disease. (September 2022) Authors: Peerani, Farhad; Watt, Makayla; Ismond, Kathleen P; Whitlock, Reid; Ambrosio, Lindsy; Hotte, Naomi; Mitchell, Nicholas; Bailey, Robert J; Kroeker, Karen; Dieleman, Levinus A; Siffledeen, Jesse; Lim, Allen; Wong, Karen; Halloran, Brendan P; Baumgart, Daniel C; Taylor, Lorian; Raman, Maitreyi; Mads... Journal: Therapeutic advances in gastroenterology Issue: Volume 15(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Issue 10340 (28th May 2022) Authors: Ferrante, Marc; Panaccione, Remo; Baert, Filip; Bossuyt, Peter; Colombel, Jean-Frederic; Danese, Silvio; Dubinsky, Marla; Feagan, Brian G; Hisamatsu, Tadakazu; Lim, Allen; Lindsay, James O; Loftus, Edward V; Panés, Julián; Peyrin-Biroulet, Laurent; Ran, Zhihua; Rubin, David T; Sandborn, William J... Journal: Lancet Issue: Volume 399:Issue 10340(2022) Page Start: 2031 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Issue 10340 (28th May 2022) Authors: D'Haens, Geert; Panaccione, Remo; Baert, Filip; Bossuyt, Peter; Colombel, Jean-Frederic; Danese, Silvio; Dubinsky, Marla; Feagan, Brian G; Hisamatsu, Tadakazu; Lim, Allen; Lindsay, James O; Loftus, Edward V; Panés, Julian; Peyrin-Biroulet, Laurent; Ran, Zhihua; Rubin, David T; Sandborn, William J... Journal: Lancet Issue: Volume 399:Issue 10340(2022) Page Start: 2015 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Single Crystalline 4H-SiC MEMS Devices with N-P-N Epitaxial Structure. Issue 1693 (18th June 2014) Authors: Zhao, Feng; Lim, Allen; Chen, Zhibang; Huang, Chih-Fang Journal: MRS proceedings Issue: Issue 1693:(2014) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗